April 8, 2021

Accelerating an Orphan Therapy to Market

Click here to learn more >>

This case study shares the work of Cytiva’s Fast Trak Services team to help accelerate development of a process for cGMP production of material for toxicology studies. Frequent communication between the Fast Trak team and the client ensured transparency while protecting customer’s intellectual properties. Cytiva scientists worked closely with Roivant Sciences to facilitate tech transfer, and a cGMP manufacturing process was developed. As a result, 400 g of RVT 801 was produced for toxicology studies.

Tags: vaccine, Xcellerex, upstream, Fast Trak